Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Jul;30(1):140–143. doi: 10.1111/j.1365-2125.1990.tb03754.x

The effect of age on the pharmacokinetics of ifosfamide.

M J Lind 1, J M Margison 1, T Cerny 1, N Thatcher 1, P M Wilkinson 1
PMCID: PMC1368286  PMID: 2167716

Abstract

The effect of age on the pharmacokinetics of ifosfamide was studied in 20 patients with advanced non small cell lung cancer. A positive correlation was found between the elimination half-life of ifosfamide and age (r = 0.48, 0.05 less than P less than 0.01). This was due to an increase in volume of distribution with age (r = 0.66, 0.001 less than P less than 0.01). Total plasma clearance, renal clearance and non renal clearance did not change with age. Age did not affect the autoinduction of ifosfamide metabolism. Further studies are needed to demonstrate any adverse effects of ifosfamide in the elderly.

Full text

PDF
140

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen L. M., Creaven P. J., Nelson R. L. Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat Rep. 1976 Apr;60(4):451–458. [PubMed] [Google Scholar]
  2. BROCK N., HOHORST H. J. UBER DIE AKTIVIERUNG VON CYCLOPHOSPHAMID IN VIVO UND IN VITRO. Arzneimittelforschung. 1963 Dec;13:1021–1031. [PubMed] [Google Scholar]
  3. Brock N. The oxazaphosphorines. Cancer Treat Rev. 1983 Sep;10 (Suppl A):3–15. doi: 10.1016/s0305-7372(83)80002-4. [DOI] [PubMed] [Google Scholar]
  4. Bryant B. M., Jarman M., Ford H. T., Smith I. E. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet. 1980 Sep 27;2(8196):657–659. doi: 10.1016/s0140-6736(80)92703-8. [DOI] [PubMed] [Google Scholar]
  5. Catino J. J., Francher D. M., Schurig J. E. Evaluation of cis-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulfate on L1210 leukemia in vitro and in vivo. Cancer Chemother Pharmacol. 1986;18(1):1–4. doi: 10.1007/BF00253053. [DOI] [PubMed] [Google Scholar]
  6. Connors T. A., Cox P. J., Farmer P. B., Foster A. B., Jarman M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol. 1974 Jan 1;23(1):115–129. doi: 10.1016/0006-2952(74)90318-9. [DOI] [PubMed] [Google Scholar]
  7. Crooks J., O'Malley K., Stevenson I. H. Pharmacokinetics in the elderly. Clin Pharmacokinet. 1976;1(4):280–296. doi: 10.2165/00003088-197601040-00003. [DOI] [PubMed] [Google Scholar]
  8. EDELMAN I. S., LEIBMAN J. Anatomy of body water and electrolytes. Am J Med. 1959 Aug;27:256–277. doi: 10.1016/0002-9343(59)90346-8. [DOI] [PubMed] [Google Scholar]
  9. Klein H. O., Wickramanayake P. D., Christian E., Coerper C. Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557). Cancer. 1984 Sep 15;54(6 Suppl):1193–1203. doi: 10.1002/1097-0142(19840915)54:1+<1193::aid-cncr2820541317>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  10. Klotz U., Avant G. R., Hoyumpa A., Schenker S., Wilkinson G. R. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975 Feb;55(2):347–359. doi: 10.1172/JCI107938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lind M. J., Margison J. M., Cerny T., Thatcher N., Wilkinson P. M. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res. 1989 Feb 1;49(3):753–757. [PubMed] [Google Scholar]
  12. Margison J. M., Wilkinson P. M., Cerny T., Thatcher N. A simple quantitative HPLC assay for ifosfamide in biological fluids. Biomed Chromatogr. 1986 Jun;1(3):101–103. doi: 10.1002/bmc.1130010303. [DOI] [PubMed] [Google Scholar]
  13. Sladek N. E., Doeden D., Powers J. F., Krivit W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep. 1984 Oct;68(10):1247–1254. [PubMed] [Google Scholar]
  14. Teufel G., Pfleiderer A. Ifosfamid im Vergleich zu Endoxan bei fortgeschrittenen Ovarialkarzinomen. Geburtshilfe Frauenheilkd. 1976 Mar;36(3):274–279. [PubMed] [Google Scholar]
  15. Wagner T., Heydrich D., Jork T., Voelcker G., Hohorst H. J. Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. J Cancer Res Clin Oncol. 1981;100(1):95–104. doi: 10.1007/BF00405906. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES